Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 32
- Registration Number
- NCT06892639
- Locations
- 🇺🇸
Stanford University School of Medicine, Dermatology, Redwood City, California, United States
🇺🇸Mission Dermatology, Santa Margarita, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 6
- Registration Number
- NCT04213261
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
- Conditions
- SclerodermaMorpheaScleroderma, Localized
- Interventions
- Genetic: FCX-013
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 1
- Registration Number
- NCT03740724
- Locations
- 🇺🇸
Paddington Testing Co., Inc., Philadelphia, Pennsylvania, United States
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- Conditions
- Epidermolysis Bullosa Dystrophica, Recessive
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 6
- Registration Number
- NCT02810951
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia
- Conditions
- Age-related DysphoniaDysphonia Resulting From Vocal Fold Scarring
- Interventions
- Drug: PlaceboBiological: Azficel-T (autologous fibroblasts)
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Castle Creek Biosciences, LLC.
- Target Recruit Count
- 21
- Registration Number
- NCT02120781
- Locations
- 🇺🇸
Surgery/Head and Neck, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸Dept of Otolaryngology, Stanford Univ Medical Center, Stanford, California, United States
🇺🇸NYU Langone Medical Center, New York, New York, United States
- Prev
- 1
- 2
- 3
- Next